Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV
Miller E, McGinnis K, Edelman E, Feinberg T, Gordon K, Kerns R, Marshall B, Patterson J, McRae M. Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV. AIDS And Behavior 2024, 28: 3994-4004. PMID: 39264485, PMCID: PMC11586311, DOI: 10.1007/s10461-024-04494-w.Peer-Reviewed Original ResearchMental health classesSubstance use disordersOpioid use disorderHIV statusBuprenorphine initiationVeterans Aging Cohort StudyInitiate buprenorphineMental health diagnosesAging Cohort StudyBuprenorphine treatmentMultiple pain conditionsAssociated with HIV statusInfluence treatment retentionUse disorderTreatment of opioid use disorderHigher comorbidity burdenAge of patientsClinical encountersMental healthHealth diagnosisBlack veteransHealth classesLatent class analysisCohort studyPrescription dataCOVID-19 Breakthrough Infection after Vaccination and Substance Use Disorders: A Longitudinal Cohort of People with and without HIV Receiving Care in the United States Veterans Health Administration
Soyer E, McGinnis K, Justice A, Hsieh E, Rodriguez-Barradas M, Williams E, Park L. COVID-19 Breakthrough Infection after Vaccination and Substance Use Disorders: A Longitudinal Cohort of People with and without HIV Receiving Care in the United States Veterans Health Administration. AIDS And Behavior 2024, 28: 3605-3614. PMID: 39046612, DOI: 10.1007/s10461-024-04449-1.Peer-Reviewed Original ResearchHIV statusSubstance use disordersBreakthrough infectionRisk of breakthroughAssociated with increased riskCOVID-19 breakthrough infectionsSARS-CoV-2Association of substance useSARS-CoV-2 infectionHIV treatment adherenceCD4 countHIV progressionSubstance useUnited States Veterans Health AdministrationHazard ratioIncreased riskPWHCD4PWoHHIVUse disorderVaccinated personsCohort of peopleTreatment adherenceLongitudinal cohort